- recruitingPHASE1, PHASE2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This study is testing a new drug, ART0380, for people with advanced cancer. It aims to find the safest dose, understand side effects, and see how well it works, both alone and with other treatments like gemcitabine or irinotecan.
United States · France · Spain - active not recruitingPHASE2
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
This study looks at a new drug, mirvetuximab soravtansine, with carboplatin for certain types of ovarian, primary peritoneal, or fallopian tube cancer. It's for people whose cancer has come back but responded well to previous platinum-based chemotherapy.
United States · Belgium · Canada - recruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
This study looks at a new drug, Mirvetuximab Soravtansine, for women with advanced ovarian, peritoneal, or fallopian tube cancer that has resisted previous treatments. It aims to see how safe and effective the drug is, especially for cancers with a specific protein.
United States · Australia · Belgium - recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
This study looks at a new treatment called sacituzumab tirumotecan, sometimes with another medicine called bevacizumab. We want to see if it's safe and helps women with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer getting worse, compared to standard care.
United States · Argentina · Australia - active not recruitingPHASE1
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This study is for women with advanced ovarian, fallopian tube, or peritoneal cancer that has come back and isn’t responding to standard chemotherapy. It’s testing a new approach using special immune cells from your own body, called TILs, along with other treatments to see if they can fight the cancer.
Canada